Mizuho Securities Keeps Their Buy Rating on Corvus Pharmaceuticals (CRVS)
I'm PortAI, I can summarize articles.
Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Corvus Pharmaceuticals (CRVS) with a price target of $13.00. The analyst focuses on the Healthcare sector and has an average return of 8.9% with a 50.33% success rate on stock recommendations. Corvus Pharmaceuticals holds a Strong Buy consensus among analysts, with a price target consensus of $13.33.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments